title: Rapid, quantitative mapping of anti-HIV type 1 envelope serum antibody specificities.
abstract: A new generation of extremely broad and potent neutralizing antibodies (bNAbs) has been isolated from HIV-infected subjects. This has refocused interest in the sites of vulnerability targeted by these bNAbs and in the potential for designing Envelope (Env) immunogens that display these sites. Standard methods for evaluating HIV-1 vaccine candidates do not enable epitope mapping on the HIV Env spike, the target for NAbs. To meet the need for rapid analysis of Ab specificity, we designed a multiplexed, quantitative mapping assay that can test for serum Ab competition for the binding of an HIV-1 Env gp120 to a panel of bNAbs directed to different sites of vulnerability on the Env that do not compete for one another in the assay. Using serum samples from rabbits immunized with various DNA prime/gp120 protein boost vaccines we were able to detect serum Ab competition for multiple classes of bNAbs in the postimmune samples that were significantly higher than background competition detected in samples obtained prior to vaccination. Importantly, application of this novel assay to our ongoing HIV-1 Env viral vector studies in mice has allowed us to distinguish qualitative differences in the Ab elicited by various regimens that ELISA cannot. Furthermore, pooled immunoglobulin from HIV-infected donors (HIVIg) competes for binding to the bNAb panel whereas a control pool from HIV-negative donors does not, highlighting the utility of this assay for human studies. This novel assay will add value in rational immunogen design and in the detailed, qualitative evaluation of binding and, potentially, neutralizing Abs elicited by natural infections and HIV-1 vaccine candidates.
authors: International AIDS Vaccine Initiative Design and Development Laboratory, Brooklyn, NY 11220, USA. rpowell@iavi.org
authors: Rebecca L R
authors: RL
authors: Powell
authors: Ross W B
authors: RW
authors: Lindsay
authors: Aaron
authors: A
authors: Wilson
authors: Alexei
authors: A
authors: Carpov
authors: Svetlana
authors: S
authors: Rabinovich
authors: Simon
authors: S
authors: Hoffenberg
authors: Michael J
authors: MJ
authors: Caulfield
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology; D000918:Antibody Specificity / Q000276:immunology*; D001667:Binding, Competitive; D004797:Enzyme-Linked Immunosorbent Assay; D018604:Epitope Mapping; D015483:HIV Antibodies / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008297:Male; D051379:Mice / Q000276:immunology; D008810:Mice, Inbred C57BL / Q000276:immunology; D011817:Rabbits / Q000276:immunology
chemical_list: D057134:Antibodies, Neutralizing; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120
references: J Virol. 2011 Oct;85(20):10730-40
references: 21835798
references: J Virol. 2012 Mar;86(6):3393-7
references: 22258252
references: Science. 2009 Oct 9;326(5950):285-9
references: 19729618
references: Nature. 1998 Jun 18;393(6686):648-59
references: 9641677
references: Science. 2011 Sep 16;333(6049):1633-7
references: 21764753
references: PLoS Pathog. 2010 Aug 05;6(8):e1001028
references: 20700449
references: J Virol. 1994 Dec;68(12):8312-20
references: 7525987
references: Vaccine. 1998 Nov;16(19):1803-11
references: 9795384
references: J Virol. 2006 Feb;80(3):1414-26
references: 16415019
references: J Immunol Methods. 2011 Sep 30;372(1-2):71-7
references: 21781970
references: Virology. 2010 Sep 30;405(2):513-23
references: 20663531
references: J Virol. 2010 Apr;84(7):3382-95
references: 20089658
references: J Virol. 2011 Jan;85(2):905-15
references: 20980495
references: J Virol. 2003 Jun;77(12):6965-78
references: 12768015
references: J Virol. 2004 Sep;78(17):9233-42
references: 15308718
references: J Virol. 2013 May;87(10):5372-83
references: 23468492
references: Methods Enzymol. 2000;326:430-40
references: 11036656
references: Nature. 2011 Sep 22;477(7365):466-70
references: 21849977